Clinical trial NCT00510133: A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)
Official title: A Phase II Study of Active Immunotherapy With GRNVAC1, Autologous Mature Dendritic Cells Transfected With mRNA Encoding Human Telomerase Reverse Transcriptase, in Patients With Acute Myelogenous Leukemia in Complete Clinical Remission
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Myelogenous Leukemia
Lead sponsor: Asterias Biotherapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2007-08-01
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase II study to evaluate the safety, feasibility and efficacy of immunotherapy with GRNVAC1 in patients with AML.

Detailed description: This is a multicenter, open-label evaluation of feasibility, safety and immunotherapy in patients with AML in complete clinical remission. Patients will undergo leukapheresis prior to or shortly after completing consolidation chemotherapy. Dendritic cells will be transfected with the messenger RNA encoding human telomerase reverse transcriptase (hTERT) and a portion of the lysosome-associated membrane protein LAMP-1 (LAMP), matured, aliquoted, and cryopreserved. The final autologous vaccine product is referred to as GRNVAC1. Patients will be vaccinated with weekly for 6 weeks,will "rest" for 4 weeks, then will receive 6 boost injections, each administered every other week for 12 weeks. Patients will be followed every 4 weeks until Week 54, then every 3 months for 1 year, then every 6 months up to approximately 5 years from the first vaccination or until relapse/progression.

Eligibility criteria: Inclusion Criteria:

* AML in first complete remission (CR1) or in second complete remission (CR2) with CR1 \>/= 6 months
* Has completed at least one cycle of consolidation chemotherapy within past 6 months
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Adequate hepatic/renal function

Exclusion Criteria:

* CR1 and good risk cytogenetic features \[t(15;17), t(8;21), inv(16) or t(16:16)\]
* Central nervous system or leptomeningeal disease
* Allogeneic stem cell transplant planned or expected
* Documented allergy to penicillin or beta-lactam antibiotics
* Active or ongoing autoimmune disease
* Clinically significant pulmonary or cardiovascular disease

Primary outcomes:
measure: Feasibility will be assessed by examining whether enough cells are collected during leukapheresis, whether enough vaccine is manufactured for at least 2 injections, and whether the patient is still in remission when the vaccine is released.
timeFrame: 1 year
Secondary outcomes:
measure: Immunological response, defined as the proportion of patients with a positive induction of hTERT-specific T cells to twice the pre-vaccination level, the proportion of patients with DTH, and event-free survival.
timeFrame: 2 years
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University School of Medicine
state: Georgia
city: Maywood
country: United States
facility: Loyola University Medical Center
state: Illinois
city: Saint Louis
country: United States
facility: Washington University School of Medicine, Siteman Cancer Center
state: Missouri
city: Omaha
country: United States
facility: University of Nebraska Medical Center
state: Nebraska
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Dallas
country: United States
facility: UT Southwestern Medical Center
state: Texas
Study officials:
affiliation: Washington University School of Medicine
name: John F DiPersio, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References: